MarketPulse

obefazimod

3 articles
BenzingaBenzinga··Vandana Singh

Abivax Dismisses M&A Speculation, Plans Capital Raise Before Trial Readout

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.
LLYAZNABVXFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

Eli Lilly Poised to Challenge AstraZeneca in Abivax Bidding War

AstraZeneca has exclusive access to Abivax data until March 23. If it misses deadline, Eli Lilly could rejoin bidding for French biotech valued by 1,600% surge.
LLYAZNABVXacquisitionbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Abivax Sa

Abivax Demonstrates Anti-Fibrotic Potential of Obefazimod at ECCO 2026

Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.
ABVXPhase 3 clinical trialsbiomarkers